Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

VeraDermics Inc. Secures Licensing of First-in-Class Antiviral Targeting the Treatment of Molluscum Contagiosum and other Poxviruses
  • USA - English


News provided by

VeraDermics

Aug 23, 2022, 09:00 ET

Share this article

Share toX

Share this article

Share toX

VDMC-7269 is the lead asset from a poxvirus-targeting antiviral development program and is potentially a best-in-indication antiviral for molluscum contagiosum with a profile suggestive for low-dose efficacy and a wide therapeutic index

WEST HARTFORD, Conn., Aug. 23, 2022 /PRNewswire-PRWeb/ -- VeraDermics Incorporated, developer of drugs for dermatology, today announced that it has entered into a definitive license agreement with the University of Pennsylvania (Penn) for patent rights covering a newly developed compound for the specific treatment of molluscum contagiosum developed by Penn and Fox Chase Chemical Diversity Center, Inc. (FCCDC) – adding to VeraDermic's growing dermatology portfolio. The lead compound identification reflects nearly a decade of research by leading experts in poxvirus replication led by Robert Ricciardi, Ph.D., Chair of Basic and Translational Sciences at the University of Pennsylvania School of Dental Medicine, and Allen Reitz, Ph.D., Chief Executive Officer, and Rick Scott, Ph.D., VP, Research, of FCCDC.

The lead pre-clinical compound, VDMC-7269, is a potent replication inhibitor designed to block the poxvirus that causes molluscum contagiousum. The licensing of VDMC-7269 demonstrates VeraDermics' continued commitment to dermatology and to targeting dermatologic conditions lacking in FDA approved therapeutics. VeraDermics intends to bring VDMC-7269 to the clinic with molluscum contagiosum as the lead indication for development.

"As a dermatologist, molluscum contagiosum is one of the most frustrating-to-treat conditions that I encounter in my clinical practice," said Tim Durso, M.D., President and Chief Executive Officer of VeraDermics. "Molluscum primarily affects young children, and many existing treatment options are poorly tolerated by this patient population. If approved, an effective topical treatment for molluscum contagiosum could result in a paradigm shift in the treatment of this condition which affects millions of patients every year."

Molluscum contagiosum affects approximately 6 million Americans, the majority of whom are younger than 14 years of age. It is one of the most common reasons that children visit a pediatric dermatologist. Despite its prevalence, there are no FDA-approved prescription treatments for the condition. While existing treatments are often designed to be locally destructive (e.g. cryotherapy, cantharidin) or utilize non-specific antiviral properties, VDMC-7269 is specifically designed to target molluscum virus replication. Targeting a specific protein in the molluscum viral replication process that is structurally distinct from its human counterpart is expected to give VDMC-7269 a wide therapeutic window when treating patients.

"We have been working on developing novel antivirals for the treatment of the poxviruses such as molluscum contagiosum together with Prof. Robert Ricciardi of the University of Pennsylvania since 2014," said Allen Reitz, P.h.D., Chief Executive Officer of FCCDC. "This work includes the discovery of VDMC-7269, whose activity is particularly exciting because it represents a defined molecular target to treat the disease. Preclinical data suggest VDMC-7269 is a potent inhibitor of viral replication and is suitable for topical use. We are very excited that VeraDermics will advance this program further because molluscum contagiosum is currently undertreated and represents a large commercial opportunity." Dr. Rick Scott of FCCDC was the Principal Investigator on the key Phase II Small Business Innovation Research Grant (SBIR) grant from the NIH that enabled the successful completion of this project, including the discovery of VDMC-7269.

"The discovery of VDMC-7269 involved identifying a novel method for screening this drug as well as using genetic and structure-guided approaches coupled with medicinal chemistry to identify and target a protein essential for replication of molluscum contagiosum virus," says Dr. Ricciardi "This work entailed the talents and strong collaboration of scientists from both the University of Pennsylvania and FCCDC. I am very pleased that VeraDermics, with its dedication and strong expertise in dermatological drugs, will be moving the development of VDMC-7269 in the direction of clinical application."

By adding VDMC-7269 to its pipeline, VeraDermics aims to create a best-in-class treatment for molluscum contagiosum.

"The poxvirus antiviral development program is the perfect addition to VeraDermics' existing dermatology pipeline, and is consistent with our team's vision to leverage our end-user knowledge as board-certified dermatologists to identify therapeutics that address key unmet needs in our field," said Reid Waldman, M.D., Chief Operating Officer at VeraDermics. "If approved, this product candidate and the remainder of our pipeline can benefit from the synergy of a shared salesforce in dermatology. We are very excited to have the opportunity to develop such a promising asset based on nearly a decade of hard work from our colleagues at the University of Pennsylvania and Fox Chase Chemical Diversity Center."

Research that led to the development of licensed patent rights was supported by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health under award numbers R44AI125005 and R41AI162385.

About VeraDermics Inc.:
VeraDermics Inc. is a dermatology-focused pharmaceutical company with a pipeline of patient-friendly therapeutics aimed at helping individuals affected by skin diseases. VeraDermics portfolio includes therapeutics addressing common warts, genital warts, alopecia areata, molluscum contagiosum, and beyond . Find out more at http://www.veradermics.com.

About Fox Chase Chemical Diversity Center:
Fox Chase Chemical Diversity Center, Inc. (FCCDC) is based in Doylestown, Pennsylvania, USA at the Pennsylvania Biotechnology Center and is affiliated with the Pennsylvania Drug Discovery Institute (PDDI). FCCDC conducts early-stage drug discovery research including target validation, medicinal chemistry, in vitro pharmacology, and ADME characterization. FCCDC's goal is to transition innovative biomedical research technologies into fully-fledged drug discovery and development programs for evaluation in human clinical trials and eventual commercialization. Please visit fc-cdci.com.

Media Contact

Reid Waldman, VeraDermics, 913-787-6489, [email protected]

SOURCE VeraDermics

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.